Healthcare Costs Associated With Type 1 Diabetes in Adults With a Commercial, Medicaid, or Medicare Coverage in US Clinical Practice

Author(s)

Halhol S1, Stokes ME2, Li Q3, Dex T4, Wilson L4
1Evidera, Paris, Île-de-France, France, 2Evidera, Montreal, QC, Canada, 3Evidera, Boston, MA, USA, 4Sanofi, Bridgewater, NJ, USA

Presentation Documents

OBJECTIVES: To estimate healthcare costs among adult patients with type 1 diabetes (T1D) in routine clinical practices in the US.

METHODS: This retrospective cohort study analysed Merative MarketScan® data (1-Jan-2014–30-Jun-2019) for adults (≥18 years) with prevalent T1D, defined as ≥2 claims for T1D ≥30 days apart, a ratio of T1D to type 2 diabetes diagnosis codes >0.5 with either a glucagon prescription or no record for oral hypoglycemics (except metformin), or a urine acetone test prescription prior January 2017 (index). Continuous health plan enrolment was required during 12-month baseline and ≥1 month of follow-up. Annualized T1D-related costs during follow-up were reported by health plan (Commercial, Medicare, or Medicaid).

RESULTS: A total of 73,861 Commercial (mean age [SD]: 44.8 [12.9] years; 48.1% female), 21,726 Medicare (73.6 [6.6] years; 47.7% female), and 10,959 Medicaid patients (45.4 [14.2] years; 64.7% female) were included (median follow-up: 30, 12, 30 months, respectively). Annualized T1D-related costs were highest for Medicaid patients ($29,706), followed by Medicare ($23,036) and Commercial patients ($17,487). Inpatient care was the primary cost driver, comprising 59% (Medicaid), 51% (Medicare), and 32% (Commercial) of costs. Insulin and diabetes-related (including glucose monitoring and insulin pumps) accounted for more T1D-related costs in Commercial patients (27% and 14%) than Medicare (16% and 4%) or Medicaid patients (14% and 3%). Outpatient care contributed primarily to T1D-related costs of Medicare patients (20%), followed by Commercial (15%) and patients (10%). ER visits and diabetic ketoacidosis events were larger T1D-related cost drivers in Medicaid patients (6% and 6%) than Medicare (3% and 1%) and Commercial patients (4% and 2%).

CONCLUSIONS: Medicaid enrollees had higher costs than Medicare or Commercial enrollees. Inpatient care, ER visits and diabetic ketoacidosis events contributed more to Medicaid costs than for Medicare and Commercial plans, with higher insulin and equipment use in Commercial enrollees.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

RWD18

Topic

Economic Evaluation, Real World Data & Information Systems, Study Approaches

Topic Subcategory

Health & Insurance Records Systems

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×